Valion Bio Inc (VBIO)

NASD · Healthcare · Biotechnology · USA

Valion Bio Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Valion Bio is a biopharmaceutical company developing Entolimod, a recombinant TLR5 agonist for acute radiation syndrome and oncology indications including neutropenia, thrombocytopenia, and mucositis. The company also operates Velocity Bioworks, a contract development and manufacturing organization subsidiary. Valion Bio pursues regulatory approval and government procurement for its lead programs.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Valion Bio Inc stock.

Our verdict on VBIO

Undervalued: intrinsic value $2.57 per share, market price $0.54, margin of safety 79.0% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $2.57; the price of $0.54 is 79% below that value.

More on VBIO

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Is VBIO undervalued or overvalued?

VBIO is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.57; the price of $0.54 is 79% below that value.

What is the intrinsic value of VBIO?

$2.57 per share (as of the 2026-11-17 close), against a market price of $0.54. That is a margin of safety of 79.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.